Literature DB >> 22957537

Importance of cholesterol in dopamine transporter function.

Kymry T Jones1, Juan Zhen, Maarten E A Reith.   

Abstract

The conformation and function of the dopamine transporter (DAT) can be affected by manipulating membrane cholesterol, yet there is no agreement as to the impact of cholesterol on the activity of lipid-raft localized DATs compared with non-raft DATs. Given the paucity of information regarding the impact of cholesterol on substrate efflux by the DAT, this study explores its influence on the kinetics of DAT-mediated DA efflux induced by dextroamphetamine, as measured by rotating disk electrode voltammetry (RDEV). Treatment with methyl-β-cyclodextrin (mβCD), which effectively depletes total membrane cholesterol--uniformly affecting cholesterol-DAT interactions in both raft and non-raft membrane domains--reduced both DA uptake and efflux rate. In contrast, disruption of raft-localized DAT by cholesterol chelation with nystatin had no effect, arguing against a vital role for raft-localized DAT in substrate uptake or efflux. Supranormal repletion of cholesterol-depleted cells with the analog desmosterol, a non-raft promoting sterol, was as effective as cholesterol itself in restoring transport rates. Further studies with Zn(2+) and the conformationally biased W84L DAT mutant supported the idea that cholesterol is important for maintaining the outward-facing DAT with normal rates of conformational interconversions. Collectively, these results point to a role for direct cholesterol-DAT interactions in regulating DAT function.
© 2012 The Authors Journal of Neurochemistry © 2012 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22957537      PMCID: PMC3517300          DOI: 10.1111/jnc.12007

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  77 in total

1.  Insulin modulates cocaine-sensitive monoamine transporter function and impulsive behavior.

Authors:  Anton N M Schoffelmeer; Benjamin Drukarch; Taco J De Vries; François Hogenboom; Dustin Schetters; Tommy Pattij
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

Review 2.  Lipid raft microdomains and neurotransmitter signalling.

Authors:  John A Allen; Robyn A Halverson-Tamboli; Mark M Rasenick
Journal:  Nat Rev Neurosci       Date:  2006-12-29       Impact factor: 34.870

Review 3.  Dopamine release mediated by the dopamine transporter, facts and consequences.

Authors:  Vincent Leviel
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

4.  Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment.

Authors:  May A Beydoun; Lori L Beason-Held; Melissa H Kitner-Triolo; Hind A Beydoun; Luigi Ferrucci; Susan M Resnick; Alan B Zonderman
Journal:  J Epidemiol Community Health       Date:  2010-09-14       Impact factor: 3.710

Review 5.  How addictive drugs disrupt presynaptic dopamine neurotransmission.

Authors:  David Sulzer
Journal:  Neuron       Date:  2011-02-24       Impact factor: 17.173

Review 6.  The effects of statins on mood: a review of the literature.

Authors:  Alison While; Louise Keen
Journal:  Eur J Cardiovasc Nurs       Date:  2012-03       Impact factor: 3.908

7.  Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT.

Authors:  M Laura Cremona; Heinrich J G Matthies; Kelvin Pau; Erica Bowton; Nicole Speed; Brandon J Lute; Monique Anderson; Namita Sen; Sabrina D Robertson; Roxanne A Vaughan; James E Rothman; Aurelio Galli; Jonathan A Javitch; Ai Yamamoto
Journal:  Nat Neurosci       Date:  2011-03-13       Impact factor: 24.884

8.  Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study.

Authors:  Manju A Kurian; Yan Li; Juan Zhen; Esther Meyer; Nebula Hai; Hans-Jürgen Christen; Georg F Hoffmann; Philip Jardine; Arpad von Moers; Santosh R Mordekar; Finbar O'Callaghan; Evangeline Wassmer; Elizabeth Wraige; Christa Dietrich; Timothy Lewis; Keith Hyland; Simon Heales; Terence Sanger; Paul Gissen; Birgit E Assmann; Maarten E A Reith; Eamonn R Maher
Journal:  Lancet Neurol       Date:  2010-11-25       Impact factor: 44.182

9.  Impaired striatal Akt signaling disrupts dopamine homeostasis and increases feeding.

Authors:  Nicole Speed; Christine Saunders; Adeola R Davis; W Anthony Owens; Heinrich J G Matthies; Sanaz Saadat; Jack P Kennedy; Roxanne A Vaughan; Rachael L Neve; Craig W Lindsley; Scott J Russo; Lynette C Daws; Kevin D Niswender; Aurelio Galli
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

10.  The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors.

Authors:  Kyle C Schmitt; Maarten E A Reith
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

View more
  43 in total

1.  Palmitoylation by Multiple DHHC Enzymes Enhances Dopamine Transporter Function and Stability.

Authors:  Danielle E Bolland; Amy E Moritz; Daniel J Stanislowski; Roxanne A Vaughan; James D Foster
Journal:  ACS Chem Neurosci       Date:  2019-04-19       Impact factor: 4.418

2.  The cellular membrane as a mediator for small molecule interaction with membrane proteins.

Authors:  Christopher G Mayne; Mark J Arcario; Paween Mahinthichaichan; Javier L Baylon; Josh V Vermaas; Latifeh Navidpour; Po-Chao Wen; Sundarapandian Thangapandian; Emad Tajkhorshid
Journal:  Biochim Biophys Acta       Date:  2016-05-06

3.  Thermal Stability of Dopamine Transporters.

Authors:  Siim Kukk; Vladimir Stepanov; Jaak Järv
Journal:  J Membr Biol       Date:  2015-03-27       Impact factor: 1.843

Review 4.  Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets.

Authors:  Lijun Dai; Li Zou; Lanxia Meng; Guifen Qiang; Mingmin Yan; Zhentao Zhang
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

5.  Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity.

Authors:  Joseph Webb; Auriel A Willette
Journal:  Neurobiol Aging       Date:  2016-10-13       Impact factor: 4.673

6.  Flotillins regulate membrane mobility of the dopamine transporter but are not required for its protein kinase C dependent endocytosis.

Authors:  Tatiana Sorkina; John Caltagarone; Alexander Sorkin
Journal:  Traffic       Date:  2013-03-11       Impact factor: 6.215

Review 7.  Regulation of monoamine transporters and receptors by lipid microdomains: implications for depression.

Authors:  Joanne J Liu; Adrienne Hezghia; Saame Raza Shaikh; Joshua F Cenido; Ruth E Stark; J John Mann; M Elizabeth Sublette
Journal:  Neuropsychopharmacology       Date:  2018-06-28       Impact factor: 7.853

Review 8.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

Review 9.  Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease.

Authors:  Joanne J Liu; Pnina Green; J John Mann; Stanley I Rapoport; M Elizabeth Sublette
Journal:  Brain Res       Date:  2014-12-08       Impact factor: 3.252

Review 10.  Mechanisms of dopamine transporter regulation in normal and disease states.

Authors:  Roxanne A Vaughan; James D Foster
Journal:  Trends Pharmacol Sci       Date:  2013-08-20       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.